Akorn, Inc. News Releases http://investors.akorn.com/ Akorn, Inc. News Releases en Akorn to Present at the Jefferies 2019 Global Healthcare Conference http://investors.akorn.com/news-releases/news-release-details/akorn-present-jefferies-2019-global-healthcare-conference LAKE FOREST, Ill. , May 30, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY . Thu, 30 May 2019 07:59:00 -0400 Akorn, Inc. News Releases 13596 Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% http://investors.akorn.com/news-releases/news-release-details/akorn-receives-fda-approval-azelastine-hydrochloride-nasal-spray LAKE FOREST, Ill. , May 20, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Azelastine Mon, 20 May 2019 16:05:00 -0400 Akorn, Inc. News Releases 13581 Akorn to Present at the RBC Capital Markets Healthcare Conference http://investors.akorn.com/news-releases/news-release-details/akorn-present-rbc-capital-markets-healthcare-conference LAKE FOREST, Ill. , May 20, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY . Mon, 20 May 2019 08:01:00 -0400 Akorn, Inc. News Releases 13566 Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance http://investors.akorn.com/news-releases/news-release-details/akorn-provides-preliminary-first-quarter-2019-results-and-full -Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced Tue, 07 May 2019 07:05:00 -0400 Akorn, Inc. News Releases 13486 Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5% http://investors.akorn.com/news-releases/news-release-details/akorn-receives-fda-approval-loteprednol-etabonate-ophthalmic LAKE FOREST, Ill. , April 18, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Loteprednol Thu, 18 Apr 2019 17:00:00 -0400 Akorn, Inc. News Releases 13461 Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) http://investors.akorn.com/news-releases/news-release-details/akorn-receives-fda-approval-fluticasone-propionate-nasal-spray LAKE FOREST, Ill. , April 18, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Fluticasone Thu, 18 Apr 2019 16:05:00 -0400 Akorn, Inc. News Releases 13456 Akorn to Report First Quarter 2019 Financial Results and Host Conference Call http://investors.akorn.com/news-releases/news-release-details/akorn-report-first-quarter-2019-financial-results-and-host LAKE FOREST, Ill. , April 15, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Tuesday, May 7, 2019 outlining its first quarter 2019 financial results. Mon, 15 Apr 2019 13:56:00 -0400 Akorn, Inc. News Releases 13441 Akorn Names Erislandy (Dandy) Dorado-Boladeres as Executive Vice President of Global Quality http://investors.akorn.com/news-releases/news-release-details/akorn-names-erislandy-dandy-dorado-boladeres-executive-vice LAKE FOREST, Ill. , March 21, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (NASDAQ: AKRX), today announced that Dandy Dorado-Boladeres has been named as Executive Vice President of Global Quality, effective March 25, 2019. Mr. Dorado brings decades of pharmaceutical industry experience and expertise with Thu, 21 Mar 2019 07:00:00 -0400 Akorn, Inc. News Releases 13386 Akorn Comments on Favorable Court Order http://investors.akorn.com/news-releases/news-release-details/akorn-comments-favorable-court-order LAKE FOREST, Ill. , March 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) announced today that the Delaware Court of Chancery has denied a request by Fresenius Kabi AG to bring a fraud claim against Akorn.   On February 20 , Fresenius filed a proposed amended counterclaim seeking to add a Fri, 01 Mar 2019 17:17:00 -0500 Akorn, Inc. News Releases 13366 Akorn Provides Fourth Quarter and Full Year 2018 Results http://investors.akorn.com/news-releases/news-release-details/akorn-provides-fourth-quarter-and-full-year-2018-results LAKE FOREST, Ill. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the year ended 2018. Fourth Quarter 2018 and Recent Business Highlights Net revenue was $153 million , a decline of $33 Thu, 28 Feb 2019 07:00:00 -0500 Akorn, Inc. News Releases 13356